• Product NameCEP-18770 (Delanzomib)
• Brief DescriptionInhibitors
• Purification90.00%
• Biological ActivityCEP-18770 (Delanzomib) is an orally active inhibitor of the chymotrypsin-like activity of proteasome with IC50 of 3.8 nM, with only marginal inhibition of the tryptic and peptidylglutamyl activities of the proteosome. Phase 1/2.
• Target Nameproteasome inhibitor
• CAS No. 847499-27-8
• Calculated MW 413.28
• Formulation C21H28BN3O5
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:B([C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(=N1)C2=CC=CC=C2)(O)O
  Pathways:Proteases/Proteasome; Ubiquitination
  Receptor:Chymotrypsin-like proteasome
  Boling pt:
  Melting pt:
  Solubility:DMSO:83 mg/mL (200.83 mM)Ethanol:83 mg/mL (200.83 mM)Water:<1 mg/mL (<1 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Piva R,et al. Blood. 2008,111(5),2765-2775.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting